Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.


Journal

Science (New York, N.Y.)
ISSN: 1095-9203
Titre abrégé: Science
Pays: United States
ID NLM: 0404511

Informations de publication

Date de publication:
06 05 2022
Historique:
pubmed: 16 3 2022
medline: 10 5 2022
entrez: 15 3 2022
Statut: ppublish

Résumé

We provide two methods for monitoring reinfection trends in routine surveillance data to identify signatures of changes in reinfection risk and apply these approaches to data from South Africa's severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic to date. Although we found no evidence of increased reinfection risk associated with circulation of the Beta (B.1.351) or Delta (B.1.617.2) variants, we did find clear, population-level evidence to suggest immune evasion by the Omicron (B.1.1.529) variant in previously infected individuals in South Africa. Reinfections occurring between 1 November 2021 and 31 January 2022 were detected in individuals infected in all three previous waves, and there has been an increase in the risk of having a third infection since mid-November 2021.

Identifiants

pubmed: 35289632
doi: 10.1126/science.abn4947
pmc: PMC8995029
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabn4947

Références

Rev Med Virol. 2022 Jan;32(1):e2260
pubmed: 34043841
Nature. 2022 Mar;603(7902):679-686
pubmed: 35042229
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Cell. 2021 Aug 5;184(16):4220-4236.e13
pubmed: 34242578
N Engl J Med. 2021 Apr 8;384(14):1372-1374
pubmed: 33691060
Science. 2021 Mar 25;:
pubmed: 33766944
Nature. 2021 May;593(7857):130-135
pubmed: 33684923
N Engl J Med. 2021 Jun 24;384(25):2453-2454
pubmed: 33826815
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Nature. 2021 Apr;592(7854):438-443
pubmed: 33690265
Nat Med. 2021 Apr;27(4):622-625
pubmed: 33654292
JAMA. 2021 Apr 13;325(14):1467-1469
pubmed: 33646292
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
Euro Surveill. 2017 Mar 30;22(13):
pubmed: 28382917
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Am J Epidemiol. 1990 Feb;131(2):373-5
pubmed: 2296988

Auteurs

Juliet R C Pulliam (JRC)

South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Cari van Schalkwyk (C)

South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.

Nevashan Govender (N)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.

Anne von Gottberg (A)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Cheryl Cohen (C)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Michelle J Groome (MJ)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Jonathan Dushoff (J)

South African DSI-NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA), Stellenbosch University, Stellenbosch, South Africa.
McMaster University, Hamilton, Ontario, Canada.

Koleka Mlisana (K)

National Health Laboratory Service, Johannesburg, South Africa.
School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.

Harry Moultrie (H)

National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH